Alephoson Biopharmaceuticals Limited is proud to announce that it has been awarded third place in the SAPA (Sino-American Pharmaceutical Professionals Association) Roadshow held on June 25-26, 2021. This recognition is a testament to the company’s commitment to innovation and its mission to improve global healthcare through biopharmaceutical research and development.
The SAPA Roadshow is an annual event that brings together professionals in the pharmaceutical and biotech industry, investors, and entrepreneurs to showcase the latest scientific breakthroughs, innovative technologies, and emerging companies in the field of life sciences. This year’s event was held virtually due to the ongoing COVID-19 pandemic.
Alephoson Biopharmaceuticals Limited’s presentation at the SAPA Roadshow highlighted the company’s innovative method – CePPA (Cell Penetration Protein Alternation) to treat eye diseases including macular degeneration and uveitis by using eye drops. This delivery method can greatly improve patient compliance and treatment effects. In contrast, the traditional therapy implements intraocular injections periodically and results in strong side effects as well as low patient compliance. Alephoson’s eye drop therapy has the potential to revolutionize the treatment of common eye diseases.
